Group 1 - The core viewpoint of the news is that 博睿康 (BoruiKang) is preparing for an IPO with the guidance of CITIC Securities, and it is a leading company in the brain-machine interface sector in China [1][2][3] - 博睿康 was established in November 2011 and has a core team from Tsinghua University's top global neuroscience engineering laboratory, focusing on brain-machine interface technology [2][3] - The company specializes in the research, development, production, sales, and technical services of brain-machine interface systems, providing comprehensive solutions for neuroscience research and clinical neurological disease diagnosis, treatment, and rehabilitation [3] Group 2 - As of now, 博睿康 has obtained 17 technology patents and 9 software copyrights, along with medical device production licenses and multiple high-tech product certifications [3] - The controlling shareholder of the company is 胥红来, who directly holds 12.2453% of the shares and controls an additional 11.0879% through partnerships, totaling 23.3332% [4][5] - 胥红来 serves as the chairman and general manager of the company [5]
博睿康由董事长胥红来控股23%，手握17项技术专利筹备IPO
Sou Hu Cai Jing·2026-02-05 13:15